Biopsy-verified response of severe lupus nephritis to rituximab (anti-CD20 monoclonal antibody) plus cyclophosphamide after biopsy-documented failure to respond to NIH-protocol cyclophosphamide.docVIP

  • 2
  • 0
  • 约26.81万字
  • 约 38页
  • 2017-05-16 发布于上海
  • 举报

Biopsy-verified response of severe lupus nephritis to rituximab (anti-CD20 monoclonal antibody) plus cyclophosphamide after biopsy-documented failure to respond to NIH-protocol cyclophosphamide.doc

Biopsy-verified response of severe lupus nephritis to rituximab (anti-CD20 monoclonal antibody) plus cyclophosphamide after biopsy-documented failure to respond to NIH-protocol cyclophosphamide

Available online /supplements/4/S1 Meeting abstracts 22nd European Workshop for Rheumatology Research Leiden, The Netherlands 28 February – 3 March 2002 Received: 15 January 2002 Published: 4 February 2002 Arthritis Res 2002, 4 (suppl 1) ? 2002 BioMed Central Ltd (Print ISSN 1465-9905; Online ISSN 1465-9913) Aetiopathogenesis of rheumatic diseases 1 logic effects of VEGF in SSc patients. Serum levels of VEGF were also correlated significantly with disease severity parameters including antitopoisomerase antibodies. These results suggest that therapeutic application of VEGF by

文档评论(0)

1亿VIP精品文档

相关文档